BioXcel Therapeutics, Inc. (BTAI)
| Market Cap | 24.80M -68.9% |
| Revenue (ttm) | 742,000 -14.5% |
| Net Income | -70.86M |
| EPS | -3.15 |
| Shares Out | 31.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,848,123 |
| Open | 0.8500 |
| Previous Close | 0.8900 |
| Day's Range | 0.7801 - 0.8955 |
| 52-Week Range | 0.7365 - 6.8500 |
| Beta | 0.29 |
| Analysts | Strong Buy |
| Price Target | 18.33 (+2,214.1%) |
| Earnings Date | Aug 13, 2026 |
About BTAI
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmede... [Read more]
Full Company ProfileFinancial Performance
In 2025, BioXcel Therapeutics's revenue was $642,000, a decrease of -71.67% compared to the previous year's $2.27 million. Losses were -$69.90 million, 17.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price target is $18.33, which is an increase of 2,214.10% from the latest price.
News
BioXcel Therapeutics Quarterly report: Q2 2026
BioXcel Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in...
BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)
Reports Q1 revenue $206,000, consensus $381,490. “The first quarter was marked by tremendous progress, achieving a major regulatory milestone and developing the IGALMI commercial launch plan for the a...
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia...
BioXcel Therapeutics Quarterly report: Q1 2026
BioXcel Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
BioXcel Therapeutics Earnings release: Q1 2026
BioXcel Therapeutics released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
BioXcel Therapeutics Transcript: Investor update
IGALMI is poised for a major market expansion as the first FDA-approved at-home treatment for acute agitation in bipolar and schizophrenia, with strong support from physicians, patients, and payers. Launch preparations target a Q1 2027 rollout, with ongoing efforts to secure payer access, educate prescribers, and explore partnerships.
BioXcel Therapeutics Slides: Investor update
BioXcel Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 23, 2026.
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn.
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
BioXcel Therapeutics enrolls first patients in BXCL501 trial
BioXcel Therapeutics (BTAI) announced the enrollment of the first patients in a U.S. Department of War-funded Phase 2a clinical trial evaluating BXCL501 for the treatment of acute stress reactions, al...
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War ...
BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $5 from $6 and keeps a Buy rating on the shares. The firm cites the company’s recent and…
BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA
BioXcel Therapeutics (BTAI) announced that the FDA has accepted its supplemental new drug application, or sNDA, for approval of Igalmi for at-home use in the acute treatment of agitation associated…
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outp...
BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)
Reports Q4 revenue $256,000, consensus $151,520. “2025 was a successful year for our Company, setting the stage for the potential label expansion of IGALMI in the at-home setting and continuing…
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia
BioXcel Therapeutics Annual report: Q4 2025
BioXcel Therapeutics has published its Q4 2025 annual report on March 27, 2026.
BioXcel Therapeutics Earnings release: Q4 2025
BioXcel Therapeutics released its Q4 2025 earnings on March 27, 2026, summarizing the period's financial results.
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative m...
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative m...
BioXcel price target lowered to $6 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $6 from $10 and keeps a Buy rating on the shares. The firm cites the recent and anticipated…
BioXcel Therapeutics announces results from Phase 2 trial of BXCL501
BioXcel Therapeutics (BTAI) announced positive topline results from a Phase 2 investigator-sponsored trial evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use ...
BioXcel Therapeutics announces results from Phase 2 trial of BXCL501
BioXcel Therapeutics (BTAI) announced positive topline results from a Phase 2 investigator-sponsored trial evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use ...
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXCL...